Transaction Overview: South Korea's First Institutional Bitcoin Treasury Company
Parataxis Holdings LLC has entered into a definitive agreement to acquire a controlling interest in South Korean biotech company Bridge Biotherapeutics, Inc. (KOSDAQ: 288330) for KRW 25 billion ($18.3 million). The deal marks the creation of South Korea's first institutionally backed Bitcoin treasury company. Upon completion, Bridge Biotherapeutics will be renamed Parataxis Korea and continue trading on the KOSDAQ exchange, subject to shareholder approval and customary closing conditions. This transaction represents a significant pivot for the clinical-stage biotech firm, which has been developing therapeutics for ulcerative colitis, fibrotic diseases, and cancers since its founding in 2015, transforming it into a hybrid entity that integrates a Bitcoin treasury alongside its core biotechnology operations.
Leadership Changes and Strategic Shift
Edward Chin, Founder and CEO of Parataxis Holdings and Co-Founder & CEO of Parataxis Capital, will join Bridge Bio's Board of Directors following the transaction's completion. Andrew Kim, Partner at Parataxis Capital, will assume the CEO role and also join the board, while Bridge Bio co-founder James Jungkue Lee will continue leading the core biotech business. This leadership reshuffle reflects the company's dual focus: sustaining its therapeutic R&D pipeline while building a significant Bitcoin treasury. The move is inspired by the growing interest in BTC treasury strategies seen in companies like Strategy in the US and Metaplanet in Japan, indicating that institutional interest in Bitcoin treasury approaches is increasing globally.
Executive Commentary: Global Inspiration and Korean Market Potential
Andrew Kim emphasized, “Inspired by the growing interest in BTC treasury strategies seen in companies like Strategy in the US and Metaplanet in Japan, we believe institutional interest in this space is increasing globally. We see South Korea as an important market in the evolution of BTC adoption. Our intent is to support institutional access to BTC exposure while emphasizing sound corporate governance and disciplined capital management.” Edward Chin added, “We are incredibly excited to create the first BTC treasury company in South Korea backed by an institutional-grade platform. Given the strategic nature of BTC on the global stage and its finite supply, we believe that building and growing a company like Parataxis Korea and accumulating a BTC treasury will benefit our shareholders as well as the country over the long run.”
Timeline and Advisory Team
The transaction is expected to close following shareholder approval at a meeting scheduled for August. Shin & Kim LLC is serving as legal advisor, and Deloitte is acting as financial advisor. This case provides a template for other Asian listed companies exploring Bitcoin treasury strategies, particularly as regulatory frameworks continue to mature in the region. The hybrid model — combining existing biotech operations with a Bitcoin treasury — could attract investors seeking exposure to both therapeutic innovation and digital asset appreciation.